A Randomized Phase III Study of Arfolitixorin Versus Leucovorin with 5-Fluorouracil, Oxaliplatin and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial.

Josep Tabernero Takayuki Yoshino Sebastian Stinzing Aimery deGramont Peter Gibbs Derek J Jonker Peter Nygren Christos A Papadimitriou Gerald W Prager Roger Tell Heinz-Josef Lenz

Published in: Cancer research communications (2023)

The study failed to demonstrate clinical benefit of arfolitixorin (120 mg/m2) over leucovorin. However, it provides some useful insights from the first-line treatment setting, including the effect of gene expression on outcomes.

Keyphrases

phase iii
gene expression
metastatic colorectal cancer
clinical trial
open label
phase ii
study protocol
adipose tissue
skeletal muscle
weight loss
glycemic control